All Articles

Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.

EMPIRE-1 Phase 2/3 Trial Results Indicate Fluorine 18 Fluciclovine PET/CT Utilization May Confer Event-Free Survival Advantage

Prostate Cancer

Web Exclusives

The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.

Recent Review Article Highlights PSMA-Based Radioligands Diagnostic Value in Prostate Cancer

Prostate Cancer

Web Exclusives

Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.

Researchers Released Data from a Clinical Trial Investigating Fluorine 18 Fluciclovine PET/CT Use to Identify Targets for Site-Directed Therapy

Prostate Cancer

Web Exclusives

Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.

Phase 3 INDICATE Trial Evaluating the Use of Apalutamide in Patients with Biochemical Recurrence of Prostate Cancer

Prostate Cancer

Web Exclusives

Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.

Androgen Deprivation Therapy at Time of Fluorine 18 Fluciclovine PET/CT More Likely to Return a Positive Scan

Prostate Cancer

Web Exclusives

Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.

Best Practices in GU Navigation

The Impact of Real-World Data on Efficacy and Safety of Agents for Advanced Renal-Cell Cancer

By Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; Virginia Seery, CRNP, MSN

Interview with the Innovators

Video Library

The last 10 to 15 years has seen important advances in the management of advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss how real-world efficacy and safety data influence the conversations they have with their patients with advanced renal-cell carcinoma regarding treatment options.

Sotorasib Demonstrates Clinical Benefit in Patients with NSCLC Harboring KRASᴳ¹²ᶜ

Lung Cancer

Web Exclusives

In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups.

Lung Cancer Incidence in the United States Declines Among All Patient Subgroups

Lung Cancer

Web Exclusives

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment.

Severe Adverse Events from Immune Checkpoint Inhibitor Therapy Are Rare

Lung Cancer

Web Exclusives

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment.